http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03033019-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c96c0571d8cc5c35643d78202863e008 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-00727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-147 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-007 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-14 |
| filingDate | 2002-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5843e23f01ac5982f235a934a25ead6d |
| publicationDate | 2003-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-03033019-A3 |
| titleOfInvention | Inducing separation of the posterior hyaloid from the retina |
| abstract | A process for inhibiting vascular proliferation separately introduces components into the eye to generate plasmin in the eye in amounts to induce complete posterior vitreous detachment where the vitreoretinal interface is devoid of cortical vitreous remnants. The process administers a combination of recombinant lysine-plasminogen, at least one recombinant plasminogen activator and a gaseous adjuvant. The components are introduced into the vitreous in an amount effective to induce substantially complete posterior vitreous detachment from the retina without causing inflammation of the retina. The gaseous adjuvant material is introduced into the vitreous simultaneously with or after the recombinant lysine-plasminogen and recombinant plasminogen activator such as recombinant urokinase to compress the vitreous against the retina while the composition induces the complete posterior vitreous detachment. |
| priorityDate | 2001-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.